Actelion Receives Canada Approval For Uptravi
Actelion Ltd
The approval is "a major milestone", Chief Executive Jean-Paul Clozel said in a statement, adding that the company is working to make the drug available to patients in Canada "as soon as possible".
Analysts have said Uptravi could reap more than $1 billion in global sales annually at its peak.
(Reporting by Joshua Franklin; editing by Brenna Hughes Neghaiwi)
Published by Medicaldaily.com
Join the Discussion